Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

ide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted marketing approval for the Company's first product, Soliris for all patients with PNH and the Company began commercial sale of Soliris in the U.S. during April 2007. In June 2007, the European Commission granted marketing approval for Soliris in the European Union for all patients with PNH. The Company is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is actively pursuing development of other antibody product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: http://www.alexionpharm.com.

This news release contains forward-looking statements, including statements related to potential benefits and commercial potential for Soliris, and interest about Soliris in the patient, physician and payor communities. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to us on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 Research and ... Arthritis Drugs Market 2014-2018" report to their offering. ... a chronic disease that leads to inflammation and pain in ... and ankles. In addition, it causes inflammation of the tissues ... The symptoms of RA begin slowly, usually just ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
(Date:7/28/2014)... July 28, 2014 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution provider ... diagnostic imaging centers in China , ... of Directors declared a special cash dividend of US$0.30 ... ("ADS")) on the Company,s outstanding ordinary shares. The total ...
Breaking Medicine Technology:Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2
... (Nasdaq: BMRN ) today announced the initiation of ... polymerase (PARP) inhibitor in development for the treatment of genetically-defined ... show survival benefits in cancer patients with tumors that have ... agents, and BMN 673 appears to have superior potency, selectivity, ...
... RF Technologies®, a leading provider of radio frequency ... announced a distributor agreement with Universal Hospital Services, ... management and service solutions. Through the agreement, which ... offer the RF Technologies Safe Place® Infant and ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3RF Technologies® Announces Distributor Agreement With Universal Hospital Services 2
(Date:7/28/2014)... The report “Industrial Enzymes Market by Types ... Agents, Bio-Fuel, Animal Feed), & Geography - Global ... the global industrial enzymes market with analysis and ... It also identifies driving and restraining factors for ... trends, opportunities, burning issues, winning imperatives, and challenges. ...
(Date:7/28/2014)... (Boston)-- Researchers from Boston University School of Medicine (BUSM) ... increase the risk of developing Alzheimer,s disease (AD). The ... new drug treatment options that target PLXNA4 specifically. These ... , AD is the most frequent age-related dementia affecting ... 65 and older, and more than 40 percent of ...
(Date:7/28/2014)... "Fist bumping" transmits significantly fewer bacteria than ... cultural expectation of hand-to-hand contact between patients and ... August issue of the American Journal of ... Association for Professionals in Infection Control and Epidemiology ... of Biological, Environmental, and Rural Sciences at Aberystwyth ...
(Date:7/28/2014)... 2014) -- Researchers from The University of Texas Health Science ... institutions have identified a combination of pills that cures 9 ... drugs sofosbuvir and simeprevir, with or without ribavirin, cured 93 ... by patients, according to the study published today in ... the U.S. , Eric Lawitz, M.D., clinical professor in ...
(Date:7/28/2014)... WA (PRWEB) July 28, 2014 ... consulting and care management organizations, has published a ... low-cost approach to engaging patients and families in ... environments at multiple hospitals, the toolkit provides a ... huddle” with patients and their families early in ...
Breaking Medicine News(10 mins):Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Researchers identify potential biomarker for AD 2Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2
... help college students retain and integrate new information to ... abstract that will be presented Tuesday, June 14, in ... of the Associated Professional Sleep Societies LLC (APSS). ... microeconomics test was preserved after a 12-hour period that ...
... Getting six to nine hours of sleep per night is ... ratings for depression, suggests a research abstract that will be ... the 25th Anniversary Meeting of the Associated Professional Sleep Societies ... sleep duration of six to nine hours per night had ...
... , MONDAY, June 13 (HealthDay News) -- Spending ... increased overall and especially among certain groups of patients, a ... aged 18 and older who used glaucoma medication between 2001 ... medications increased from $445 in 2001 to $557 in 2006. ...
... Ill. June 13, 2011 A new ... preparation are associated with relatively high adenoma (precancerous ... substantially decreases colonoscopy effectiveness and may mandate an ... context of suboptimal bowel preparation, of all adenomas ...
... National Institutes of Health researchers have identified a new pathway ... The study provides insights about the interaction between a toxic ... chromosomes like aglets, the plastic tips that bind the ends ... National Human Genome Research Institute (NHGRI) appears in the June ...
... China? Boys are considered a greater asset for farming, but ... want a boy at any cost doubled? Sociologist ... families in China choose to abort girls. When ... born in China, a nationwide campaign was started against sex-selective ...
Cached Medicine News:Health News:Sleep can boost classroom performance of college students 2Health News:The good life: Good sleepers have better quality of life and less depression 2Health News:Polyp miss rates high for colonoscopies done after poor bowel preparation 2Health News:Polyp miss rates high for colonoscopies done after poor bowel preparation 3Health News:Polyp miss rates high for colonoscopies done after poor bowel preparation 4Health News:NIH researchers find new clues about aging 2Health News:NIH researchers find new clues about aging 3Health News:NIH researchers find new clues about aging 4Health News:Has China's campaign against female feticide done more harm than good? 2
... is a threaded titanium anchor, ... procedures. The anchor features wide ... to optimize bone purchase, as ... to prevent suture binding. Fastin ...
... 5mm Super Revo Suture Anchor offers a ... a mini-open rotator cuff repair. The cutting ... is pre-threaded with two #2 strands of ... suture management are avoided with the Independent ...
... 5mm Super Revo Suture Anchor offers a ... a mini-open rotator cuff repair. The cutting ... is pre-threaded with two #2 strands of ... suture management are avoided with the Independent ...
The Linvatec UltraFix Suture Anchor System's smooth surface until deployed eliminates tissue, bone and suture damage and its ultra smooth eyelet hole preserves suture integrity....
Medicine Products: